



**Mark W. Lingen,
DDS, PhD, FRCPath**

Current appointment:

Professor

Institution/ University where currently appointed:

Department of Pathology
University of Chicago, USA

Areas of special interests:

Tumor Angiogenesis, oral premalignancy, oral cancer screening, chemoprevention

Web links:

<http://pathology.uchicago.edu/>

<http://htrc.uchicago.edu/>

<http://www.oooojournal.net/>

Mark Lingen is a Professor of Pathology at the University of Chicago, Pritzker School of Medicine. He completed his dental school training, residency in Oral & Maxillofacial Pathology as well as his PhD in Cellular and Molecular Pathology at Northwestern University. Dr. Lingen is the Editor in Chief for the journal Oral Surgery, Oral Medicine, Oral Pathology Oral Radiology (TripleO). His research dealing with tumor angiogenesis and oral cancer has resulted in over 100 publications. Dr. Lingen is a Diplomate of the American Board of Oral & Maxillofacial Pathology. He is a Fellow of the American College of Dentists, the International College of Dentists, and the Royal College of Pathologists.

Recent/ significant publications:

- Hasina R, Fekete MJ, Martin L, Qi X-M, Brigaudeau C, Pramanik R, Edith I. Cline, Coignet L, **Lingen MW**. 2006. NOL7 is a Nucleolar Candidate Tumor Suppressor Gene in Cervical Cancer that Modulates the Angiogenic Phenotype. *Oncogene*, 25:588-598.

- Hasina R, Whipple M, Kuo WP, Martin L, Ohno-Machado L, **Lingen, MW**. 2008. Intertumoral Angiogenic Heterogeneity in Head and Neck Squamous Cell Carcinoma: Biologic and Therapeutic Implications. *Laboratory Investigation*, 88:342-353.
- **Lingen MW**, Kalmar J, Karrison T, Speight P. 2008. Critical Evaluation of Current Diagnostic Aids for the Detection of Oral Cancer. *Oral Oncology*, 44:10-22.
- Hasina R, Martin LE, Jones C, Jalil A, **Lingen MW**. 2009. ABT-510 is an Effective Chemopreventive Agent in the 4NQO Mouse Model of Oral Carcinogenesis. *Cancer Prevention Research*, 2:385-393.
- Mankame TP, Zhou G, **Lingen MW**. 2010. Identification and Characterization of the Human NOL7 Gene Promoter. *Gene*, 456:36-44.
- Rethman MP, Carpenter W, Cohen EEW, Epstein JB, Evans C, Flaitz C, Graham F, Hujoel P, Kalmar J, Koch W, Kohn W, Lambert PM, **Lingen MW**, Oettmeier B, Patton LL, Perkins D, Reid BC, Sciubba JJ, Tomar SL, Wyatt A. 2010. Evidence-Based Clinical Recommendations on Screening for Oral Squamous Cell Carcinomas. *JADA*, 141:509-520.
- Zhou G, Jones C, **Lingen MW**. 2010. Identification and Functional Characterization of the Nuclear and Nucleolar Localization Signals in NOL7. *BMC Cell Biology*, 11:74-93.
- Zhou G, Hasina R, Wroblewski K, Mankame TP, Doci CL, **Lingen MW**. 2010. Dual Inhibition of VEGFR and EGFR is an Effective Chemopreventive Strategy in the Mouse 4NQO Model of Oral Carcinogenesis. *Cancer Prevention Research*, 3:1493-1502.
- **Lingen MW**, Pinto A, Mendes RA, Franchini R, Czerninski R, Tilakaratne WM, Partridge M, Peterson DE, Woo S-B. 2011. Genetics/Epigenetics of Oral Premalignancy: Current Status and Future Research. *Oral Diseases*, 17:7-22.
- Doci CL, Mankame TP, Langerman A, Ostler KR, Godley LA, Salgia R, **Lingen MW**. 2012. Characterization of point mutations and promoter methylation of the NOL7 tumor suppressor gene NOL7 in cervical cancer cell lines and tumor specimens. *International Journal of Gynecological Pathology*, 31:15-24.
- Jordan RC, **Lingen MW**, Perez-Ordóñez B, He X, Pickard R, Inman A, Koluder M, Jiang B, Wakely P, Xiao W, Gillison ML. 2012. Validation of methods for HPV status determination for oropharyngeal cancers in United States cooperative group trials *American Journal of Surgical Pathology*, 7:945-954.
- Mankame TP, **Lingen MW**. 2012. The Rb tumor suppressor positively regulates transcription of the anti-angiogenic protein NOL7. *Neoplasia*, 14:1213-1222.
- **Lingen MW**, Xiao W, Schmidt A, Jiang B, Pickard R, Kreinbrink P, Garcia-Perdonez B, Jordan RC, Gillison ML. 2013. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. *Oral Oncology*, 49:1-8.
- Doci CL, Zhou G, **Lingen MW**. 2013. The Novel Tumor Suppressor NOL7 Post-transcriptionally Regulates Thrombospondin-1 Expression. *Oncogene*, 32:4377-4388.